骨转移用药狄诺塞麦售价多少？

(denosumab) is a recombinant human monoclonal antibody that inhibits osteoclast activity and reduces bone resorption and bone transformation by inhibiting RANKL. Since its launch in the United States in 2010, denosumab has gradually become one of the important drugs for the treatment of malignant tumors and osteoporosis. Today we will learn more about the price of denosumab, a bone metastasis drug?

In 2018, denosumab (denosumab) entered the rapid review channel of the National Medical Products Administration and is currently the only drug used to treat giant cell tumor of bone. The price of denosumab available in China is relatively expensive, while the Turkish version of denosumab, the American Amgen Xgeva 120mg, is priced around $1,500. Patients in need can go abroad to purchase medicines, or they can obtain medicines through domestic professional overseas medical service organizations (such as Medical Companion Travel) and have them delivered directly to their homes, ensuring they are genuine.

Denosumab (denosumab) injection is a human immunoglobulin G2 (IgG2) monoclonal antibody with high specificity and affinity for RANKL. By combining with RANKL, the drug prevents the activation of the RANK signaling pathway of osteoclasts, breaking the "vicious cycle" of cancer bone metastasis, thereby achieving the purpose of inhibiting tumor growth and reducing bone destruction. Denosumab was approved by the NMPA in May 2019 for the treatment of giant cell tumors of bone that are unresectable or in which surgical resection may result in severe functional disability, including adults and adolescent patients with skeletal maturity (defined as at least 1 mature long bone and body weight ≥45 kg).

Denosumab (denosumab) is not only targeted when used to prevent bone-related events, but also has a direct anti-tumor effect; the clinical efficacy of denosumab is better than that of bisphosphonates, and it is still effective for patients who have failed bisphosphonate treatment; denosumab is safe, and patients taking denosumab are less likely to have nephrotoxic side effects; denosumab is easy to use, bisphosphonates require intravenous injection, while denosumab is subcutaneously injected, making it more convenient to use.

Denosumab (denosumab) is indicated for the treatment of postmenopausal women with osteoporosis who are at high risk for fracture, specifically those with a history of osteoporotic fracture or multiple risk factors for fracture; or those who have failed or are intolerant to other available osteoporosis treatments;

The above is the price content of (denosumab), I hope it can help you!

Recommended related hot articles: /newsDetail/82253.html